| 2024/04/18 17:35:39 | |
|---|---|
| Price | |
| 45.095 EUR | |
| Difference | 0.52% (0.24) |
General attributes
| ISIN | US1101221083 |
| Symbol | BMY |
| Exchange | Xetra |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 91,981 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 45.00 EUR (26) |
| Ask (Ask size) | 45.25 EUR (158) |
| Open | 44.75 EUR |
| High | 45.285 EUR |
| Low | 44.725 EUR |
| Close (prev. day) | 44.86 EUR |
| VWAP | 45.00691 EUR |
| Volume (pcs) | 3,240 |
| Trading volume | 145,822.39 |
| Number of trades | 48 |
| Last size | 0 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: BRISTOL-MYERS SQUIBB CO. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/18 17:35:39 | |
|---|---|
| Price | |
| 45.095 EUR | |
| Difference | 0.52% (0.24) |
General attributes
| ISIN | US1101221083 |
| Symbol | BMY |
| Exchange | Xetra |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 91,981 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 45.00 EUR (26) |
| Ask (Ask size) | 45.25 EUR (158) |
| Open | 44.75 EUR |
| High | 45.285 EUR |
| Low | 44.725 EUR |
| Close (prev. day) | 44.86 EUR |
| VWAP | 45.00691 EUR |
| Volume (pcs) | 3,240 |
| Trading volume | 145,822.39 |
| Number of trades | 48 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -17.10% | -29.87% | -17.38% |
| Perf (abs.) | -9.31 | -19.21 | -9.49 |
| Beta | 0.61 | 0.45 | 0.31 |
| Volatility | 24.00 | 21.10 | 20.76 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 45.483 EUR (2,984) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 47.820 EUR (2,287) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 46.781 EUR (2,414) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 52.407 EUR (1,619) |
| YTD High | date | 50.200 EUR (2024/03/28) |
| YTD Low | date | 44.350 EUR (2024/02/06) |
| 52 Weeks High | date | 64.600 EUR (2023/04/24) |
| 52 Weeks Low | date | 44.200 EUR (2023/11/20) |
All listings for BRISTOL-MYERS SQUIBB CO.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/04/18 | 17:35 | 45.095 EUR | 0.15 | 48 |
| Vienna Stock Exchange | 2024/04/19 | 09:05 | 45.305 EUR | 0.00 | 1 |
| Tradegate | 2024/04/19 | 09:54 | 45.27 EUR | 0.01 | 7 |
| Stuttgart | 2024/04/19 | 08:11 | 44.93 EUR | 0.00 | 1 |
| SIX Swiss Exchange | 2019/07/03 | 05:55 | 45.30 USD | 0.00 | 1 |
| SIX Swiss Exchange | 2019/06/28 | 17:35 | 44.39 CHF | 0.00 | 1 |
| NYSE | 2024/04/18 | 22:00 | 48.30 USD | 525.57 | 93,278 |
| Munich | 2024/04/19 | 08:03 | 45.09 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/04/19 | 10:00 | 48.115 USD | 0.00 | 1 |
| Hanover | 2024/04/19 | 08:00 | 45.015 EUR | 0.00 | 1 |
| Hamburg | 2024/04/19 | 08:00 | 45.015 EUR | 0.00 | 1 |
| Frankfurt | 2024/04/19 | 09:05 | 45.07 EUR | 0.00 | 1 |
| Euronext Milan MTF Trading After Hours | 2024/02/28 | 18:52 | 46.90 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/04/18 | 17:44 | 44.97 EUR | 0.01 | 5 |
| Duesseldorf | 2024/04/19 | 09:30 | 44.885 EUR | 0.00 | 2 |
| Berlin | 2024/04/19 | 08:09 | 44.88 EUR | 0.00 | 1 |
Company Logo
Contact Details
| BRISTOL MYERS SQUIBB CO. |
| - - |
| Route 206 & Province Line Road - 08543 Princeton |
| Telefon: +1-609-252-4621 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: BRISTOL-MYERS SQUIBB CO. | |
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ. |
Members of Management Board
| Deepak Bhatt | Member of Board of Directors |
| Julia Haller | Member of Board of Directors |
| Karen Vousden | Member of Board of Directors |
| Manuel Hidalgo Medina | Member of Board of Directors |
| Derica Rice | Member of Board of Directors |
| Gerald Storch | Member of Board of Directors |
| Paula Price | Member of Board of Directors |
| Peter Arduini | Member of Board of Directors |
| Phyllis Yale | Member of Board of Directors |
| Theodore Samuels | Member of Board of Directors |
| Chris Boerner | Chairman of Managing Board |
| Adam Lenkowsky | Member of Executive Committee |
| Amanda Poole | Member of Executive Committee |
| Cari Gallman | Member of Executive Committee |
| David Elkins | Member of Executive Committee |
| Greg Meyers | Member of Executive Committee |
| Karin Shanahan | Member of Executive Committee |
| Kim Jablonski | Member of Executive Committee |
| Lynelle B. Hoch | Member of Executive Committee |
| Pamela Fisher | Member of Executive Committee |
| Peter S. Paine III | Member of Executive Committee |
| Robert Plenge | Member of Executive Committee |
| Samit Hirawat | Member of Executive Committee |
| Sandra Leung | Member of Executive Committee |